ResearcherChinese PLA General HospitalActive in the last 2 years

Lingling Meng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-5516-9888; OpenAlex author ID A5100298603. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

Baseline and dynamic neutrophil-to-lymphocyte ratio predicts overall survival in unresectable pancreatic cancer following dose-escalated SBRT: a ten-year longi… Last author DOI 10.3389/fmolb.2026.1877894 ↗
Impact of radiotherapy on the survival of unresectable locally advanced pancreatic cancer. Last author DOI 10.1016/j.asjsur.2024.04.019 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yupeng Di · 1 shared paper, 2026 · strength 0.43
- Paper Baseline and dynamic neutrophil-to-lymphocyte ratio predicts overall survival in unresectable pancreatic cancer followi… DOI 10.3389/fmolb.2026.1877894 ↗
Jiazhao Song · 1 shared paper, 2024 · strength 0.31
- Paper Impact of radiotherapy on the survival of unresectable locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2024.04.019 ↗
Yingjie Wang · 1 shared paper, 2024 · strength 0.31
- Paper Impact of radiotherapy on the survival of unresectable locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2024.04.019 ↗
Yupeng Di · 1 shared paper, 2024 · strength 0.31
- Paper Impact of radiotherapy on the survival of unresectable locally advanced pancreatic cancer. DOI 10.1016/j.asjsur.2024.04.019 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.